SquadX, a popular Web3 community growth entity, has partnered with Orexn, a next-gen Web3 engagement and reward platform. The partnership aims to merge the dat SquadX, a popular Web3 community growth entity, has partnered with Orexn, a next-gen Web3 engagement and reward platform. The partnership aims to merge the dat

SquadX Taps Orexn to Advance Global Web3 Growth

2025/12/14 17:00
2 min read
web3

SquadX, a popular Web3 community growth entity, has partnered with Orexn, a next-gen Web3 engagement and reward platform. The partnership aims to merge the data-led growth mechanism with swiftly expanding reward ecosystem to advance Web3 adoption. As per SquadX’s official social media announcement the collaboration will take into account diverse community-led campaigns. Hence, the development is set to substantially improve accessibility, fortify marketing endeavors, and bolster community growth within the decentralized sector.

SquadX and Orexn Partnership Accelerates Web3 Growth with Rewarding Campaigns

The partnership between SquadX and Orexn underscores a strategic move that aligns community incentives and technology. In this respect, SquadX, which is famous for an analytics-driven approach for project scaling, will deliver the infrastructure for campaign optimization. Additionally, Orexn will offer its expertise related to airdrop and launchpool mechanics.

Keeping this in view, the collaboration focuses on the provision of relatively impactful campaigns. The respective campaigns will reportedly attract consumers and retain them via noteworthy rewards. Thus, this initiative plays a crucial role in elevating the position of SquadX within the competitive Web3 market, where projects require consistent struggle for long-term engagement. Particularly, by leveraging the reward mechanism of Orexn, which has gained wider traction by successfully engaging numerous consumers, SquadX intends to amplify growth strategies. Additionally, the reward integration into data-led campaigns guarantees that consumers get motivation for active participation.

Simultaneously, the joint effort establishes a sustainable growth cycle, letting projects leverage both loyalty and visibility. Backing both Web3 ventures and well-established entities, the development provides a blueprint for community scaling to balance innovation by adding tangible incentives. At the same time, the move could set exclusive benchmarks when it comes to campaign execution, allowing decentralized projects to prioritize user experience and technology.

Advancing Sustainable and Scalable Web3 Expansion with Wider Accessibility and Innovation

According to SquadX, the joint endeavor is aimed at making a notable impact across diverse Web3 growth dimensions. Additionally, with stronger campaigns, improved community engagement, and enhanced accessibility, the partnership is poised to offer new opportunities for participation in highly rewarding networks, while accelerating sustainable and scalable project growth. Ultimately, the development denotes the next chapter of decentralized advancement, powered by community-first strategies and innovation.

Market Opportunity
Overtake Logo
Overtake Price(TAKE)
$0.01815
$0.01815$0.01815
-0.05%
USD
Overtake (TAKE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26